We are currently seeking a Scientist* Computational Mass Spectrometry to strengthen our Bioinformatics department. You will work in Tübingen in an interdisciplinary environment with colleagues from various other departments across the Company.
You hold a PhD in Bioinformatics or have successfully completed a similar training and are experienced in working with mass spectrometry data. You have solid programming skills in a scripting language, are familiar with SQL, and are used to working in a Linux environment.
We expect a high degree of independent working, analytical reasoning, and good communication skills in English. You embrace rapidly changing requirements with an open mind, think outside the box and show a high degree of flexibility in an environment which is marked by a constant striving for excellence. Your motivation is driven by your passion for innovation and science, and you are willing to extend your knowledge to support our scientists in developing new cancer immunotherapies.
We are a committed and inspired team and cherish the collegial, highly motivated, and family-friendly atmosphere within Immatics. Our culture allows for a high level of originality, independent thinking, and initiative. We believe in supporting our employees’ professional and social skills: We enable them to join conferences and trainings as well as to enjoy our Immatics benefits – e.g., job bike, job ticket, Health Programs, childcare benefits, relocation allowance, Company summer and winter events.
*We value diversity and inclusion. Immatics N.V. and all Immatics subsidiaries are equal opportunity employers that evaluate qualified applicants without regard to race, color, national origin, religion, sex, age, marital status, disability, veteran status, sexual orientation, gender identity, or other characteristics protected by law.
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets.
This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.